Dose-dependent von Willebrand Factor inhibition by aptamer BB-031 correlates with thrombolysis in a microfluidic model of arterial occlusion

Authors

Susan M Shea, Washington University School of Medicine in St. Louis
Kimberly A Thomas, Washington University School of Medicine in St. Louis
Rassam M G Rassam, Washington University School of Medicine in St. Louis
Emily P Mihalko, University of Pittsburgh
Christina Daniel, Washington University School of Medicine in St. Louis
Bruce A Sullenger, Duke University Medical Center
Philip C Spinella, Washington University School of Medicine in St. Louis
Shahid M Nimjee, The Ohio State University Medical Center

Journal

Pharmaceuticals

Publication Date

11-22-2022

Volume

15

Issue

12

First Page

1450

Document Type

Open Access Publication

DOI

10.3390/ph15121450

Rights and Permissions

Shea, S.M.; Thomas, K.A.; Rassam, R.M.G.; Mihalko, E.P.; Daniel, C.; Sullenger, B.A.; Spinella, P.C.; Nimjee, S.M. Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion. Pharmaceuticals 2022, 15, 1450. https://doi.org/10.3390/ph15121450 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Shea, Susan M; Thomas, Kimberly A; Rassam, Rassam M G; Mihalko, Emily P; Daniel, Christina; Sullenger, Bruce A; Spinella, Philip C; and Nimjee, Shahid M, "Dose-dependent von Willebrand Factor inhibition by aptamer BB-031 correlates with thrombolysis in a microfluidic model of arterial occlusion." Pharmaceuticals. 15, 12. 1450 (2022).
https://digitalcommons.wustl.edu/oa_4/1024

Additional Links

Supplemental material is available for this article at publisher site.